Crossmark

Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker

Crossref DOI link: https://doi.org/10.1038/s41440-020-0495-0

Published Online: 2020-07-02

Published Print: 2020-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Arai, Kiyoshi

Morikawa, Yuka

Ubukata, Naoko

Sugimoto, Kotaro
License Information

Text and Data Mining valid from 2020-07-02

Version of Record valid from 2020-07-02
More Information

Article History

Received: 9 January 2020

Revised: 19 May 2020

Accepted: 22 May 2020

First Online: 2 July 2020

Compliance with ethical standards

:

: All authors are employees of Daiichi Sankyo Co., Ltd., Tokyo, Japan.

Document is current

Any future updates will be listed below